Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 1Lymphoma 1Graft vs Host Disease 1

Interventions

Cyclosporine 5Cyclophosphamide 5Busulfan 4fludarabine phosphate 3fludarabine 3Mycophenolic Acid 3thymoglobulin 2Methotrexate 2Antilymphocyte Serum 2venetoclax 1trihexyltetradecylphosphonium chloride 1treosulfan 1tocilizumab 1Whole-Body Irradiation 1Thiotepa 1Tacrolimus 1Sirolimus 1Semustine 1Rituximab 1Radiotherapy 1Polymerase Chain Reaction 1Physical Therapy Modalities 1Peripheral Blood Stem Cell Transplantation 1Maraviroc 1Interferon alpha-2 1Immunoenzyme Techniques 1Drug Therapy 1Decitabine 1Cytarabine 1Cyclosporins 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Graft vs Host Disease × Maraviroc × Clear all
NCT02799888 2016-06-15

Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation

Affiliated Hospital to Academy of Military Medical Sciences

Phase 2 Unknown
40 enrolled
LymphoidMyeloid

Graft vs Host Disease, Lymphoma, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡